IBDEI0AS ; ; 18-NOV-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;NOV 18, 2013
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,14348,0)
 ;;=438.7^^95^841^21
 ;;^UTILITY(U,$J,358.3,14348,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14348,1,4,0)
 ;;=4^438.7
 ;;^UTILITY(U,$J,358.3,14348,1,5,0)
 ;;=5^CVA w/ Vision Changes (Late Effect)
 ;;^UTILITY(U,$J,358.3,14348,2)
 ;;=^328504
 ;;^UTILITY(U,$J,358.3,14349,0)
 ;;=438.12^^95^841^19
 ;;^UTILITY(U,$J,358.3,14349,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14349,1,4,0)
 ;;=4^438.12
 ;;^UTILITY(U,$J,358.3,14349,1,5,0)
 ;;=5^CVA w/ Dysphasia (Late Effect)
 ;;^UTILITY(U,$J,358.3,14349,2)
 ;;=^317908
 ;;^UTILITY(U,$J,358.3,14350,0)
 ;;=438.20^^95^841^20
 ;;^UTILITY(U,$J,358.3,14350,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14350,1,4,0)
 ;;=4^438.20
 ;;^UTILITY(U,$J,358.3,14350,1,5,0)
 ;;=5^CVA w/ Hemiplegia (Late Effect)
 ;;^UTILITY(U,$J,358.3,14350,2)
 ;;=^317910
 ;;^UTILITY(U,$J,358.3,14351,0)
 ;;=434.91^^95^841^22
 ;;^UTILITY(U,$J,358.3,14351,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14351,1,4,0)
 ;;=4^434.91
 ;;^UTILITY(U,$J,358.3,14351,1,5,0)
 ;;=5^CVA,Acute Onset
 ;;^UTILITY(U,$J,358.3,14351,2)
 ;;=^295738
 ;;^UTILITY(U,$J,358.3,14352,0)
 ;;=454.1^^95^841^29
 ;;^UTILITY(U,$J,358.3,14352,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14352,1,4,0)
 ;;=4^454.1
 ;;^UTILITY(U,$J,358.3,14352,1,5,0)
 ;;=5^Dermatitis,Stasis
 ;;^UTILITY(U,$J,358.3,14352,2)
 ;;=^125435
 ;;^UTILITY(U,$J,358.3,14353,0)
 ;;=424.90^^95^841^31
 ;;^UTILITY(U,$J,358.3,14353,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14353,1,4,0)
 ;;=4^424.90
 ;;^UTILITY(U,$J,358.3,14353,1,5,0)
 ;;=5^Endocarditis
 ;;^UTILITY(U,$J,358.3,14353,2)
 ;;=^40327
 ;;^UTILITY(U,$J,358.3,14354,0)
 ;;=456.1^^95^841^32
 ;;^UTILITY(U,$J,358.3,14354,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14354,1,4,0)
 ;;=4^456.1
 ;;^UTILITY(U,$J,358.3,14354,1,5,0)
 ;;=5^Esoph Varices w/o Bleed
 ;;^UTILITY(U,$J,358.3,14354,2)
 ;;=^269836
 ;;^UTILITY(U,$J,358.3,14355,0)
 ;;=403.10^^95^841^37
 ;;^UTILITY(U,$J,358.3,14355,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14355,1,4,0)
 ;;=4^403.10
 ;;^UTILITY(U,$J,358.3,14355,1,5,0)
 ;;=5^HTN w/ Renal Failure I-IV or Unspec
 ;;^UTILITY(U,$J,358.3,14355,2)
 ;;=^334271
 ;;^UTILITY(U,$J,358.3,14356,0)
 ;;=457.1^^95^841^61
 ;;^UTILITY(U,$J,358.3,14356,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14356,1,4,0)
 ;;=4^457.1
 ;;^UTILITY(U,$J,358.3,14356,1,5,0)
 ;;=5^Lymphedema,Acquired
 ;;^UTILITY(U,$J,358.3,14356,2)
 ;;=^87693
 ;;^UTILITY(U,$J,358.3,14357,0)
 ;;=436.^^95^841^74
 ;;^UTILITY(U,$J,358.3,14357,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14357,1,4,0)
 ;;=4^436.
 ;;^UTILITY(U,$J,358.3,14357,1,5,0)
 ;;=5^Stroke,Acute Ill Defined
 ;;^UTILITY(U,$J,358.3,14357,2)
 ;;=^2710
 ;;^UTILITY(U,$J,358.3,14358,0)
 ;;=451.9^^95^841^75
 ;;^UTILITY(U,$J,358.3,14358,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14358,1,4,0)
 ;;=4^451.9
 ;;^UTILITY(U,$J,358.3,14358,1,5,0)
 ;;=5^Thrombophlebitis
 ;;^UTILITY(U,$J,358.3,14358,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,14359,0)
 ;;=446.6^^95^841^76
 ;;^UTILITY(U,$J,358.3,14359,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14359,1,4,0)
 ;;=4^446.6
 ;;^UTILITY(U,$J,358.3,14359,1,5,0)
 ;;=5^Thrombotic Thrombocytopenic Purpu
 ;;^UTILITY(U,$J,358.3,14359,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,14360,0)
 ;;=435.9^^95^841^77
 ;;^UTILITY(U,$J,358.3,14360,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14360,1,4,0)
 ;;=4^435.9
 ;;^UTILITY(U,$J,358.3,14360,1,5,0)
 ;;=5^Transient Ischemic Attack
 ;;^UTILITY(U,$J,358.3,14360,2)
 ;;=^21635
 ;;^UTILITY(U,$J,358.3,14361,0)
 ;;=455.6^^95^841^58
 ;;^UTILITY(U,$J,358.3,14361,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14361,1,4,0)
 ;;=4^455.6
 ;;^UTILITY(U,$J,358.3,14361,1,5,0)
 ;;=5^Hemorrhoids
 ;;^UTILITY(U,$J,358.3,14361,2)
 ;;=^123922
 ;;^UTILITY(U,$J,358.3,14362,0)
 ;;=403.90^^95^841^34
 ;;^UTILITY(U,$J,358.3,14362,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14362,1,4,0)
 ;;=4^403.90
 ;;^UTILITY(U,$J,358.3,14362,1,5,0)
 ;;=5^HTN w/ CKD I-IV,Unspec
 ;;^UTILITY(U,$J,358.3,14362,2)
 ;;=^334272
 ;;^UTILITY(U,$J,358.3,14363,0)
 ;;=271.3^^95^842^10
 ;;^UTILITY(U,$J,358.3,14363,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14363,1,4,0)
 ;;=4^271.3
 ;;^UTILITY(U,$J,358.3,14363,1,5,0)
 ;;=5^Glucose Intolerance
 ;;^UTILITY(U,$J,358.3,14363,2)
 ;;=^64790
 ;;^UTILITY(U,$J,358.3,14364,0)
 ;;=251.2^^95^842^28
 ;;^UTILITY(U,$J,358.3,14364,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14364,1,4,0)
 ;;=4^251.2
 ;;^UTILITY(U,$J,358.3,14364,1,5,0)
 ;;=5^Hypoglycemia Nos
 ;;^UTILITY(U,$J,358.3,14364,2)
 ;;=^60580
 ;;^UTILITY(U,$J,358.3,14365,0)
 ;;=257.2^^95^842^29
 ;;^UTILITY(U,$J,358.3,14365,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14365,1,4,0)
 ;;=4^257.2
 ;;^UTILITY(U,$J,358.3,14365,1,5,0)
 ;;=5^Hypogonadism,Male
 ;;^UTILITY(U,$J,358.3,14365,2)
 ;;=^88213
 ;;^UTILITY(U,$J,358.3,14366,0)
 ;;=253.2^^95^842^32
 ;;^UTILITY(U,$J,358.3,14366,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14366,1,4,0)
 ;;=4^253.2
 ;;^UTILITY(U,$J,358.3,14366,1,5,0)
 ;;=5^Hypopituitarism
 ;;^UTILITY(U,$J,358.3,14366,2)
 ;;=^60686
 ;;^UTILITY(U,$J,358.3,14367,0)
 ;;=278.00^^95^842^39
 ;;^UTILITY(U,$J,358.3,14367,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14367,1,4,0)
 ;;=4^278.00
 ;;^UTILITY(U,$J,358.3,14367,1,5,0)
 ;;=5^Obesity (2nd dx only)
 ;;^UTILITY(U,$J,358.3,14367,2)
 ;;=^84823
 ;;^UTILITY(U,$J,358.3,14368,0)
 ;;=278.01^^95^842^38
 ;;^UTILITY(U,$J,358.3,14368,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14368,1,4,0)
 ;;=4^278.01
 ;;^UTILITY(U,$J,358.3,14368,1,5,0)
 ;;=5^Morbid Obesity
 ;;^UTILITY(U,$J,358.3,14368,2)
 ;;=^84844
 ;;^UTILITY(U,$J,358.3,14369,0)
 ;;=250.80^^95^842^9
 ;;^UTILITY(U,$J,358.3,14369,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14369,1,4,0)
 ;;=4^250.80
 ;;^UTILITY(U,$J,358.3,14369,1,5,0)
 ;;=5^DM Type II with LE Ulcer
 ;;^UTILITY(U,$J,358.3,14369,2)
 ;;=DM Type II with LE Ulcer^267846^707.10
 ;;^UTILITY(U,$J,358.3,14370,0)
 ;;=250.00^^95^842^4
 ;;^UTILITY(U,$J,358.3,14370,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14370,1,4,0)
 ;;=4^250.00
 ;;^UTILITY(U,$J,358.3,14370,1,5,0)
 ;;=5^DM Type II Dm W/O Complications
 ;;^UTILITY(U,$J,358.3,14370,2)
 ;;=^33605
 ;;^UTILITY(U,$J,358.3,14371,0)
 ;;=250.40^^95^842^5
 ;;^UTILITY(U,$J,358.3,14371,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14371,1,4,0)
 ;;=4^250.40
 ;;^UTILITY(U,$J,358.3,14371,1,5,0)
 ;;=5^DM Type II Dm with Nephropathy
 ;;^UTILITY(U,$J,358.3,14371,2)
 ;;=^267837^583.81
 ;;^UTILITY(U,$J,358.3,14372,0)
 ;;=250.50^^95^842^8
 ;;^UTILITY(U,$J,358.3,14372,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14372,1,4,0)
 ;;=4^250.50
 ;;^UTILITY(U,$J,358.3,14372,1,5,0)
 ;;=5^DM Type II w/ Ophthal Manifest
 ;;^UTILITY(U,$J,358.3,14372,2)
 ;;=DM Type II w/ Ophthal Manifest^267839^362.02
 ;;^UTILITY(U,$J,358.3,14373,0)
 ;;=250.60^^95^842^6
 ;;^UTILITY(U,$J,358.3,14373,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14373,1,4,0)
 ;;=4^250.60
 ;;^UTILITY(U,$J,358.3,14373,1,5,0)
 ;;=5^DM Type II Dm with Neuropathy
 ;;^UTILITY(U,$J,358.3,14373,2)
 ;;=^267841^357.2
 ;;^UTILITY(U,$J,358.3,14374,0)
 ;;=250.70^^95^842^7
 ;;^UTILITY(U,$J,358.3,14374,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14374,1,4,0)
 ;;=4^250.70
 ;;^UTILITY(U,$J,358.3,14374,1,5,0)
 ;;=5^DM Type II Dm with Peripheral Vasc Dis
 ;;^UTILITY(U,$J,358.3,14374,2)
 ;;=^267843^443.81
 ;;^UTILITY(U,$J,358.3,14375,0)
 ;;=250.01^^95^842^3
 ;;^UTILITY(U,$J,358.3,14375,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14375,1,4,0)
 ;;=4^250.01
 ;;^UTILITY(U,$J,358.3,14375,1,5,0)
 ;;=5^DM Type I DM W/O Complications
 ;;^UTILITY(U,$J,358.3,14375,2)
 ;;=^33586
 ;;^UTILITY(U,$J,358.3,14376,0)
 ;;=272.0^^95^842^20
 ;;^UTILITY(U,$J,358.3,14376,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14376,1,4,0)
 ;;=4^272.0
 ;;^UTILITY(U,$J,358.3,14376,1,5,0)
 ;;=5^Hypercholesterolemia, Pure
 ;;^UTILITY(U,$J,358.3,14376,2)
 ;;=Hypercholesterolemia, Pure^59973
 ;;^UTILITY(U,$J,358.3,14377,0)
 ;;=272.1^^95^842^26
 ;;^UTILITY(U,$J,358.3,14377,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14377,1,4,0)
 ;;=4^272.1
 ;;^UTILITY(U,$J,358.3,14377,1,5,0)
 ;;=5^Hypertriglyceridemia, Pure
 ;;^UTILITY(U,$J,358.3,14377,2)
 ;;=Hypertriglyceridemia, Pure^101303
 ;;^UTILITY(U,$J,358.3,14378,0)
 ;;=272.2^^95^842^23
 ;;^UTILITY(U,$J,358.3,14378,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14378,1,4,0)
 ;;=4^272.2
 ;;^UTILITY(U,$J,358.3,14378,1,5,0)
 ;;=5^Hyperlipidemia, Mixed
 ;;^UTILITY(U,$J,358.3,14378,2)
 ;;=^78424
 ;;^UTILITY(U,$J,358.3,14379,0)
 ;;=275.42^^95^842^19
 ;;^UTILITY(U,$J,358.3,14379,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14379,1,4,0)
 ;;=4^275.42
 ;;^UTILITY(U,$J,358.3,14379,1,5,0)
 ;;=5^Hypercalcemia
 ;;^UTILITY(U,$J,358.3,14379,2)
 ;;=^59932
 ;;^UTILITY(U,$J,358.3,14380,0)
 ;;=275.41^^95^842^27
 ;;^UTILITY(U,$J,358.3,14380,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14380,1,4,0)
 ;;=4^275.41
 ;;^UTILITY(U,$J,358.3,14380,1,5,0)
 ;;=5^Hypocalcaemia
 ;;^UTILITY(U,$J,358.3,14380,2)
 ;;=^60542
 ;;^UTILITY(U,$J,358.3,14381,0)
 ;;=276.7^^95^842^21
 ;;^UTILITY(U,$J,358.3,14381,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14381,1,4,0)
 ;;=4^276.7
 ;;^UTILITY(U,$J,358.3,14381,1,5,0)
 ;;=5^Hyperkalemia
 ;;^UTILITY(U,$J,358.3,14381,2)
 ;;=^60042
 ;;^UTILITY(U,$J,358.3,14382,0)
 ;;=275.2^^95^842^17
 ;;^UTILITY(U,$J,358.3,14382,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14382,1,4,0)
 ;;=4^275.2
 ;;^UTILITY(U,$J,358.3,14382,1,5,0)
 ;;=5^Hyper Or Hypomagnesemia
 ;;^UTILITY(U,$J,358.3,14382,2)
 ;;=^35626
 ;;^UTILITY(U,$J,358.3,14383,0)
 ;;=276.0^^95^842^24
 ;;^UTILITY(U,$J,358.3,14383,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14383,1,4,0)
 ;;=4^276.0
 ;;^UTILITY(U,$J,358.3,14383,1,5,0)
 ;;=5^Hypernatremia
 ;;^UTILITY(U,$J,358.3,14383,2)
 ;;=^60144
 ;;^UTILITY(U,$J,358.3,14384,0)
 ;;=276.1^^95^842^30
 ;;^UTILITY(U,$J,358.3,14384,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14384,1,4,0)
 ;;=4^276.1
 ;;^UTILITY(U,$J,358.3,14384,1,5,0)
 ;;=5^Hyponatremia
 ;;^UTILITY(U,$J,358.3,14384,2)
 ;;=Hyponatremia^60722
